Bausch Health Co. Inc. (BHC) – Accesswire
-
Bausch Health to Announce First-Quarter 2024 Results on May 2
-
Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
-
Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
-
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
-
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative
-
Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversation
-
Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
-
New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure
-
Bausch Health Companies to Present at Cowen Annual Health Care Conference
-
Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results
-
Salix Announces 2024 Gastrointestinal Health Scholars Program
-
Bausch Health Announces Board Refreshment
-
CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S.
-
Solta Medical’s Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
-
Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute
-
Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P antagonist) to Treat Ulcerative Colitis
-
DUOBRII(TM) Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec’s Public Drug Plan
-
Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day
-
The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, Accor
-
As Daylight Saving Time Comes to a Close, Bausch Health Champions Mental Health with a Spotlight on Preventing Seasonal Affective Disorder (SAD)
-
Bausch Health Announces Third-Quarter 2023 Results
-
Bausch Health Announces Third-Quarter 2023 Results
-
U.S. District Court Dismisses Norwich's Lawsuit Against the FDA
-
Bausch Health Unveils "Looking Forward" - A New DTC Television Campaign for Seasonal Affective Disorder (SAD)
-
FDA Approves Cabtreo(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide) Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older
-
New Analysis Indicates That a Majority of Overt Hepatic Encephalopathy (OHE) Patients May Face Delays in Treatment Initiation and Gaps During Treatment for Access to Treatment Indicated to Reduce Risk
-
Bausch Health to Announce Third-Quarter 2023 Results on Nov. 2
-
Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase in Chronic Liver Disease and Cirrhosis-Related Deaths Marking These as Ninth Leading Cause of Death in U.S.
-
Salix Pharmaceuticals Partners with Bellamy Young
-
League of United Latin American Citizens (LULAC) Joins OraPharma in the Fight Against Gum Disease
-
New Bausch Health Treatment PrUCERIS(R) (budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults
-
Ortho Dermatologics Announces 2023 Aspire Higher Scholarship Recipients
-
Salix to Present Data from XIFAXAN(R) (Rifaximin) Clinical Research at EASL's International Liver Congress(TM) 2023
-
Bausch Health Responds to Norwich's ANDA Tentative Approval and Lawsuit Against United States Food and Drug Administration
-
New Clinical Study Suggests the Use of OraPharma’s ARESTIN(R) (minocycline HCl) Microspheres, 1mg May Decrease Certain Pathogens in Adults with Periodontitis
-
Bausch Health Announces 2023 Annual Meeting of Shareholder Results
-
Bausch Health Observes Mental Health Awareness Month
-
Salix Pharmaceuticals to Deliver Podium Presentation at Digestive Disease Week(R) 2023
-
Bausch Health Announces First-Quarter 2023 Results
-
Ortho Dermatologics Announces U.S. Food and Drug Administration New Drug Application Filing Acceptance for Investigational Acne Treatment IDP-126 Gel
-
Salix Partners with the Colorectal Cancer Alliance on Community Screening Program
-
Bausch Health to Announce First-Quarter 2023 Results on May 4
-
New Research: More Than Half of IBS Patients Surveyed Report Waiting More Than One Year Before Discussing IBS Symptoms With Their Healthcare Provider
-
Bausch Health Announces Changes to its Board of Directors
-
Bausch Health Announces Fourth-Quarter and Full-Year 2022 Results
-
Bausch Health to Announce Fourth-Quarter and Full-Year 2022 Results on Feb. 23
-
Salix Pharmaceuticals Culminates Year-Long Constipation Awareness Campaign with New Social Media and Digital Initiatives Empowering Patients to Discuss Their Symptoms with a Health Care Provider
-
Bausch Health Announces the Unrestricting of Bausch + Lomb Under Bausch Health Debt Documents
-
Salix Will Present Rifaximin Data at AASLD's The Liver Meeting(R) 2022
-
Bausch Health Announces Third-Quarter 2022 Results
Back to BHC Stock Lookup
